14 Inhaltsverzeichnis
11. Monitoring der ART...........................................................................248
12. Prävention, Compliance, Kosten..........................................................260
Prävention................................................................................................260
Compliance..............................................................................................268
Kosten......................................................................................................272
7.
Management von Nebenwirkungen........................................................277
Gastrointestinale Beschwerden..................................................................277
Übelkeit und Erbrechen............................................................................278
Diarrhoen.................................................................................................278
Hepatotoxizität.........................................................................................279
Nierenkomplikationen..............................................................................282
Neurologische Nebenwirkungen...............................................................284
ZNS-Störungen.........................................................................................285
Knochenstoffwechsel................................................................................285
Allergien..................................................................................................287
Hämatologische Veränderungen................................................................289
Laktatazidose............................................................................................290
Spezielle Nebenwirkungen einzelner Medikamente...................................291
8.
Das Lipodystrophie-Syndrom.................................................................295
Einleitung.................................................................................................295
Klinik.......................................................................................................295
ART, Lipodystrophie, kardiovaskuläres Risiko..........................................297
Pathogenese..............................................................................................298
Diagnostik................................................................................................300
Therapie...................................................................................................302
Literatur...................................................................................................306
9.
Mitochondriale Toxizität.........................................................................309
Einleitung.................................................................................................309
Pathogenese der mitochondrialen Toxizität...............................................309
Klinisches Spektrum.................................................................................310
Monitoring und Diagnose.........................................................................313
Therapie, Prophylaxe mitochondrialer Toxizität........................................314
Literatur...................................................................................................317
10.
Resistenzen..............................................................................................321
Methoden der Resistenzbestimmung.........................................................321
Grundlagen...............................................................................................323
Interpretation genotypischer Resistenzprofile............................................329
Zusammenfassung....................................................................................341
11.
Opportunistische Infektionen (OI)..........................................................352
Leave a Comment